Table 4.
Antigen marker as a predictor of relapse for AML excluding APL
| Antigen Markers | AML excluding APL sample (n=183) | |
|---|---|---|
| OR 95%CIa | AOR 95%CIb | |
| CD2− | Referent | Referent |
| CD2+ | 0.39 (0.18, 0.83)** | 0.40 (0.17, 0.94)** |
| CD10− | Referent | Referent |
| CD10+ | 0.42 (0.18, 0.95)** | 0.37 (0.15, 0.90)** |
| CD11b− | Referent | Referent |
| CD11b+ | 0.50 (0.26, 0.95)** | 0.55 (0.28, 1.11) ns |
| CD13− | Referent | Referent |
| CD13+ | 3.44 (1.28, 9.27)** | 2.88 (1.02, 8.19)** |
| CD14− | Referent | Referent |
| CD14+ | 0.45 (0.21, 0.97)** | 0.47 (0.20, 1.11) ns |
| CD15− | Referent | Referent |
| CD15+ | 0.36 (0.17, 0.78)** | 0.42 (0.19, 0.94)** |
| CD34− | Referent | Referent |
| CD34+ | 3.10 (1.52, 6.32)** | 3.06 (1.43, 6.55)** |
| CD36− | Referent | Referent |
| CD36+ | 0.47 (0.24, 0.89)** | 0.48 (0.24, 0.95)** |
| HLA-DR− | Referent | Referent |
| HLA-DR+ | 3.05 (1.09, 8.49)** | 3.23 (1.09, 9.60)** |
| CD34−/HLA-DR− | Referent | Referent |
| CD34+/HLA-DR+ | 5.25 (2.64, 10.41)** | 5.21 (2.51, 10.84)** |
| CD11B+/CD11C+/CD36+/CD14+ (less than 3 of 4) | Referent | Referent |
| CD11B+/CD11C+/CD36+/CD14+ (at least 3 of 4) | 0.46 (0.23, 0.91)** | 0.49 (0.24, 1.02) |
a
Unadjusted Odds Ratio and 95% Confidence Intervals;
b
Adjusted Odds Ratio and 95% Confidence Intervals – adjusted for age (less than 60 years or 60+ years) and cytogenetics (good, intermediate or poor);
**
statistically significant at p<0.05;
ns: statistically not significant.